ORN0829

short T1/2 dual orexin 1/2 receptor antagonist

in clinical dev. for insomnia (Ph. II)

from ligand-based drug design

Bioorg. Med. Chem., Apr. 11, 2020

Taisho Pharmaceutical Co., Saitama, JP

ORN0829 is a dual inhibitor of orexins 1 and 2, designed to have a relatively short half life in humans for application in insomnia (to reduce side effects after waking…


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks